Company: EUDAW
Filing Date: 2025-06-24
Form Type: 424B5
Source: 0001641172-25-016185
Chunk: 0

Company: EUDA Health Holdings Ltd
Filing Date: 2025-06-24
Form: 424B5
Chunk 0
---
FILED PURSUANT TO RULE 424(b)(5)

REGISTRATION NO. 333-282723

PROSPECTUS SUPPLEMENT

(to Prospectus dated November 4, 2024)

<div align='center'>$10,000,000

EUDA HEALTH HOLDINGS LIMITED

Ordinary Shares</div>

We entered into an At The Market Offering Agreement (the “Sales Agreement”) dated June 23, 2025 with Chardan Capital Markets, LLC (“Chardan” or “Agent”), relating to our ordinary shares offered by this prospectus supplement and the accompanying prospectus. Chardan shall act as representative of the Agent. In accordance with the terms of the Sales Agreement, pursuant to this prospectus supplement and the accompanying prospectus, we may offer and sell shares of our ordinary shares, having an aggregate offering price of up to $10.0 million from time to time on or after the date of this prospectus supplement through our Agent.

This prospectus supplement should be read in conjunction with the accompanying prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the accompanying prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the accompanying prospectus, and any future amendments or supplements thereto.

Our ordinary shares are traded on Nasdaq Capital Market under the symbol “EUDA.” The last reported sale price of our ordinary shares on June 20, 2025 was $3.72 per share.

Sales of our ordinary shares, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. The Agent is not required to sell any specific number or dollar amount of securities, but will act as sales agent using commercially reasonable efforts consistent with its normal trading and sales practices on mutually agreed terms between Chardan and us. There is no arrangement for funds to be received in any escrow, trust, or similar arrangement.

The compensation payable to the Agent for sales of ordinary shares sold pursuant to the Sales Agreement will be an amount equal to (a) 3% of the gross proceeds of shares sold directly into the market pursuant to each Sales Notice or (b) 7% if sold through institutional or broker-to-broker “block